Go Back
Report Abuse

UK LSD Collaborative

Description

The UK Lysosomal Storage Disorder Patient Collaborative is an alliance of UK patient organisations representing people and families affected by lysosomal storage disorders. Its member charities collectively cover more than 70 rare and ultra-rare conditions. The collaborative advocates for access to appropriate healthcare, promotes shared understanding, consults on issues affecting the community and develops joint strategies and good practice. It acts as a collective forum rather than replacing the condition-specific information and support provided by member organisations.

The UK LSD Collaborative brings together patient organisations dedicated to supporting those affected by LSDs, a group of rare inherited metabolic disorders caused by enzyme deficiencies that lead to the toxic build-up of materials in the body’s cells. These disorders, including Niemann-Pick diseases, Gaucher disease, Fabry disease, and mucopolysaccharidoses, can affect multiple systems such as the brain, heart, skeleton, and nervous system. By working collaboratively rather than as individual groups, the UK LSD Collaborative amplifies its impact through a shared mission to:

  • Promote Joint Advocacy: Undertake collective efforts to raise awareness and understanding of LSDs among healthcare professionals, policymakers, and the public.
  • Advance Standards of Care: Develop and disseminate best practices to improve diagnosis, treatment, and support for LSD patients.
  • Enhance Wellbeing: Foster initiatives that improve the health and wellbeing of those affected by LSDs and their families.
  • Stimulate Collaboration: Establish a forum for member organisations to discuss common challenges, share ideas, and drive progress together.

Impact of the UK LSD Collaborative

The collaborative’s strength lies in its ability to unite patient organisations to achieve greater impact together. Key achievements include:

  • Promoting research into innovative treatments, such as enzyme replacement therapy, gene therapy, and substrate reduction therapy.
  • Creating a stronger, unified voice to advocate for improved healthcare services and policies for LSD patients.
  • Raising awareness of LSDs to support earlier diagnosis and intervention.
  • Enhancing support for nearly 2,500 patients and their families through shared resources and community-building initiatives.

Contact

Address
MPS House Repton Place, White Lion Road Amersham, HP7 9LP United Kingdom
Zip/Post Code
HP7 9LP
MPS House Repton Place, White Lion Road Amersham, HP7 9LP United Kingdom
Social Info
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram